Europe and Middle East & Africa Vaginal Panel Testing Market: Introduction According to the report, the vaginal panel testing market in EMEA was valued at US$ 117.5 Mn in 2020 and is projected to expand at a CAGR of 3.9% from 2021 to 2031. Vaginal panel testing is an automated qualitative in vitro diagnostic test for the direct detection of DNA targets from bacteria associated with bacterial vaginosis, candida species associated with vulvovaginal candidiasis, and trichomonas vaginalis. The test utilizes real-time polymerase chain reaction (PCR) for the amplification of specific DNA targets and utilizes fluorogenic target-specific hybridization probes to detect and differentiate DNA. Vaginal panel is intended to assist in the diagnosis of vaginal infections in women with a clinical presentation consistent with bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis. Accurate Diagnosis of Vaginal Infections Accurate screening & detection of bacterial, yeast, fungi, and viral samples in clinical pathology using vaginal testing panels has allowed less turnaround time due to their lower chances of producing false positive results due to broad coverage of microbes of different classes, sensitivity, and effectiveness for the production of results. This will help in more women undergoing diagnostic tests for vaginal testing, which, in turn, increases the number of diagnostic vaginal testing procedures. Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php? flag=B&rep_id=84178 oreover, incidence of vaginal disorders is common among young women, and around 32% of the female population struggles with different kinds of vaginal complications. Most vaginal infections are asymptomatic and hence, it is difficult to predict the initial onset. Therefore, more women are likely to undergo molecular diagnostic tests for vaginal infections, which is projected to drive the vaginal testing panels market in EMEA. Molecular Nucleic Acid Amplification Test (NAAT) to Lead Europe and Middle East & Africa Vaginal Panel Testing Market In terms of type, the vaginal panel testing market in EMEA has been bifurcated into direct molecular DNA probe and molecular nucleic acid amplification test (NAAT). The molecular nucleic acid amplification test segment held major market share in 2020. Increase in usage of molecular nucleic acid amplification test (NAAT) for the diagnosis & screening of vaginal infections due to high accuracy & sensitivity in production of results is anticipated to propel the segment in the near future. Nucleic acid amplification tests (NAATs), such as PCR, can identify as little as one organism in a sample. These employ techniques that multiply a nucleic acid sequence enzymatically, resulting in the synthesis of billions of copies in a short time. Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php? flag=CR&rep_id=84178 Bacterial Vaginosis to be Key Application Area Based on application, the vaginal panel testing market in EMEA has been classified into bacterial vaginosis, vulvovaginal candidiasis, chlamydia, gonorrhoea, trichomoniasis, and others. Bacterial vaginosis (BV) is the most prevalent cause of vaginal discharge in women of reproductive age. Although not a sexually transmitted disease, sexual activity is a risk factor for its transmission. It is linked to
Vaginal Panel Testing Market Opportunity Assessment and Forecast up to 2031
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.